A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Kulkarni PS, Gunale B, Kohli S, Lalwani S, Tripathy S, Kar S, Raut S, Kulkarni P, Apte A, Bavdekar A, Bhalla HL, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Pryor M, Hamilton S, Thakar M, Sannidhi RS, Baranwal P, Bhamare C, Dharmadhikari A, Gupta M, Poonawalla CS, Shaligram U, Kapse D; COVOVAX-Booster Study Group.
Kulkarni PS, et al.
Sci Rep. 2023 Oct 3;13(1):16579. doi: 10.1038/s41598-023-43578-w.
Sci Rep. 2023.
PMID: 37789040
Free PMC article.
Clinical Trial.